1) Executive Summary
The SNMMI Therapy Center of Excellence has many moving parts; its many task forces and working groups aim to advance the utilization of targeted radioisotope therapy by addressing education needs, reimbursement issues, credentialing and more.

2) Mission
The Society of Nuclear Medicine Molecular Imaging’s (SNMMI) Therapy Center of Excellence is an organizational component within the SNMMI dedicated to all aspects of the development and utilization of Targeted Radioisotope Therapy as an alternative to other treatments. Specifically, the new center will bring together a centralized group of all constituents within this area creating a multidisciplinary interest group whereby industry, big pharma, physicians, scientists, government and regulatory agencies as well as other stakeholders can convene to share ideas, develop education offerings and advance the utilization of radionuclide therapy.

The Therapy Center of Excellence:
(a) Provides a forum for members with similar interests
(b) Provides expertise in TRT
(c) Fosters research and education in TRT
(d) Provides outreach to other professionals and organizations
(e) Nurtures new membership in SNMMI

3) Therapy CoE Leadership
The proposed leadership is comprised of the existing TRT Outreach Working Group members.

<table>
<thead>
<tr>
<th>Officers</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>President: Suresh Srivastava, PhD</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>Vice President: Daniel Pryma, MD</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>Secretary/Treasurer: Neeta Pandit-Taskar, MD</td>
<td>June 2016 – June 2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Directors</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Baum, MD, PhD</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>Ghassan Elias El-Haddad, MD</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>Hossein Jadvar, MD, PhD, MPH, MBA, FACNM</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>AJB (Sandy) McEwan, MD</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>Erik Mittra, MD (Chair, TRT Outreach Working Group)</td>
<td>June 2016 – June 2017</td>
</tr>
<tr>
<td>Sally W. Schwarz, MS, RPh, BCNP</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>Rathan M. Subramaniam, MD, PhD, MPH, FACNM</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>Mathew L. Thakur, PhD</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>Mark Tulchinsky, MD</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>Douglas Van Nostrand, MD</td>
<td>June 2015 – June 2017</td>
</tr>
<tr>
<td>Bishnuihari Paudyal, MD</td>
<td>June 2015 – June 2017</td>
</tr>
</tbody>
</table>
4) Current Status

A. Financial
   As of May 31, 2016, the Therapy CoE has a total revenue of $24,885. This includes $4,885 in member dues. Expenses total $3,129. Revenue is generated through membership dues, which are $15 annually per member.

B. Membership
   As of July 1, 2016, there are 322 members in the Therapy CoE which includes 252 physicians and scientists and 70 technologists.

C. Member Benefits
   Member benefits include:
   • Eligibility to vote in the Therapy COE Board of Directors elections
   • Newsletter
   • Sponsored educational symposia related to members’ interests
   • Therapy CoE E-Community
   • A $20.00 discount for Therapy CoE sponsored categorical session.

5) Accomplishments for 2015-2016
   The PET CoE was formed in June 2015. Officers and board members were selected, the Center’s operating procedures and focus areas for 2015-2016 were discussed.

Overview of Proposed Center of Excellence Activities
   The center will focus on several initiatives, specific to the SNMMI Strategic Plan Goal C: Increase Appropriate Utilization of Radionuclide Therapy within the first year:

   Objective 1: Assist in the Development of Emerging Agents.
   Objective 2: Advocacy for Regulatory Approval and Reimbursement of Emerging Agents.
   Objective 3: Advanced the Use of Approved Agents.

Specific Initiatives

a. Live Courses
   SNMMI will engage key referring physician groups and designate member ambassadors for these groups to liaise, identify areas of mutual interest, and pursue opportunities such as joint educational symposia, webinars, and educational materials. In order to maintain relationships with these societies and patient groups and to emphasize the importance of the multidisciplinary approach, we will send expert speakers to the annual meetings at no cost. In conjunction with the educational offering, SNMMI will also be present in the exhibit hall to distribute supporting documents, display images that attract attention, and conduct an awareness and referral practice survey. Expert speakers will be available for questions in the exhibit booth during a peak traffic time to allow referrers to ask clinical questions and learn more. Other targets organizations include the American Thyroid Association (ATA), American Society of Hematology (ASH), American Society of Clinical Oncology Genitourinary (ASCO GU), American Society of Clinical Oncology Gastrointestinal (ASCO GI), and Endocrine Society (ENDO).

b. Collaborative Symposia
   In 2015, SNMMI held a joint symposia at the ASCO, North American Neuroendocrine Tumor Society (NANETS), and Radiological Society of North America (RSNA) annual meetings. The interactive symposia covered all aspects of TRT and brought together a group of experts in each therapeutic area to explain the advantages of TRT over other conventional therapies for specific indications. Surveys were conducted before the event to assess level of knowledge and compared to the post-education evaluation for CME. The data collected from this analysis allows us to tailor our future educational offerings for specific physician groups. All attendees were provided with supporting documents and a bibliography to support the use of TRT.
SNMMI and ASCO have had an ongoing joint session on alternating years. Since the area of nuclear medicine plays a significant role in the field of NETs, the NANETs program committee requested another joint session for the 2015 program.

Due to recent advancements in the field, SNMMI and RSNA decided to jointly create a session on “Theranostics: Contributions of Diagnostic Nuclear Medicine and Targeted Radionuclide Therapy in Clinical Oncology” as part of the RSNA annual meeting program. This session provided several examples of paired diagnostic studies and treatments using Nuclear Medicine methods. The talks addressed thyroid cancer, metastatic castrate-resistant prostate cancer, Non-Hodgkin lymphoma, PRRT, and hepatic malignant lesions.

c. Education

During the past year the Therapy CoE leadership and members actively participated in the organization and presentation of educational sessions at the 2016 SNMMI Mid-Winter Meeting in Orlando, FL and the Annual Meeting in San Diego, CA. The Therapy CoE sponsored the following sessions:

2016 Mid-Winter Meeting:
- Update on Clinical Theranostics
- The Final 2015 American Thyroid Association Guidelines: Updates and Controversies

2016 Annual Meeting:
- Categorical Session: Theranostics Beyond Neuroendocrine Tumors: Novel Applications of Targeted Radionuclide Therapy in Malignant and Nonmalignant Conditions
- CE Session: Saul Hertz Award Session: Theranostics

d. NCI Workshops

Both the NCI and SNMMI feel that targeted radionuclide therapy is important in patient care and may be underutilized in the medical community. Through these workshops, we were able to begin understanding the strengths and weaknesses of targeted radionuclide therapy as perceived by the oncology, radiation therapy, imaging and basic science communities as well as potential areas of future research in this arena. In this way, we hope to help address any pressing issues, including adequate and effective funding for research in this field. SNMMI will continue this dialogue and hold disease-specific workshops. The results of these meetings will be published in position paper(s) on the benefits, risk, and dose reduction, including dose reduction policies.

e. Committees and Task Forces

The Therapy CoE board of directors created the Committee on Radioiodine Theranostics (CORT). The committee is co-chaired by Douglas Van Nostrand, MD and Mark Tulchinsky, MD. The CORT will focus on the following objectives:

1. To educate, develop, and promote the appropriate use of radioiodine theranostics
2. To facilitate appropriate research of radioiodine theranostics
3. To encourage the participation of nuclear medicine physicians in the issues involving radioiodine theranostics such as guidelines
4. To encourage collaboration with our international colleagues in the specialty of Nuclear Medicine regarding radioiodine
6) Goals and Programs for 2016-2017
   
a. Education
   The Therapy CoE has submitted session proposals for the 2017 SNMMI Mid-Winter Meeting in Phoenix, AZ. The following sessions have been approved to be co-sponsored with the General Clinical Nuclear Medicine Council (GCNMC):
   - Management of Local-Regional and Advance Differentiated Thyroid Cancer
   - Radioactive Iodine Therapy of Benign Thyroid Disease

   The Therapy CoE is planning to sponsor educational sessions at the 2017 SNMMI Annual Meeting in Denver, CO and will submit proposals during the call for proposals.

b. Strategic Planning
   The Therapy CoE board of directors is planning a retreat for fall 2016 to finalize the Center’s business plan and main focus areas of advocacy, education, and outreach with the intent to create additional committees to focus on other disease states beyond thyroid. The board of directors will also discuss having staggered terms for board members.

c. Committees and Task Forces
   The Committee on Radiiodine Theranostics (CORT) is looking into participating in an international harmonization initiative to bring together various stakeholders in the management of differentiated thyroid cancer in order to improve patient management by harmonizing the understanding of best practices in a collegial manner. A conference in Martinique is being planned by Dr. Ciprian Draganescu and he would like to include leadership from the SNMMI, EANM, and the ATA if possible. The SNMMI and Therapy CoE leadership have requested additional information regarding the conference. The CORT is looking into working with the SNMMI staff to develop a web portal for committee members to post information and prioritize action items. The CORT is also looking into developing a survey to distribute to the Therapy CoE membership in order to see if there is any impact being made in differentiated thyroid cancer therapy.

d. Board Elections
   The Therapy CoE will have their first board of director elections in spring 2017. Current board members may elect to participate in the elections for a second term. The board of directors will discuss having staggered terms for board members beginning in June 2017.

7) Proposed Budget and Resource Requirements
   
a. Summary of Financial Needs
   The Therapy CoE requested seed funding, in the amount of $20,000 for FY2016. The Therapy CoE FY2017 budget summarizes the total resources needed to accomplish the goals set forth in the business plan.

b. Membership Dues
   Membership dues are $15 annually.

c. Resource Requirements
   No additional staff, materials, technology, or marketing support is required beyond the usual support provided by SNMMI headquarters.